[SCHEDULE 13G/A] Silo Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

This Schedule 13G/A reports that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively may beneficially own 838,081 shares of Silo Pharma common stock, representing approximately 9.99% of the outstanding common shares. That reported stake primarily reflects 833,334 shares issuable upon exercise of one warrant and 4,747 shares issuable upon exercise of a second warrant.

The filing shows the Reporting Persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over the 838,081 shares. Several additional warrants are subject to blocker provisions that prevent exercise to the extent that conversion would push ownership above certain thresholds; excluding those blocked amounts, the Reporting Persons could be deemed to beneficially own 2,392,524 shares. The filing includes a certification that the securities are not held to change or influence control of the issuer.

Positive

• Disclosure of a material stake: Reporting Persons disclose beneficial ownership of 838,081 shares, equal to 9.99% of the class.
• Warrant-based upside: The position is largely driven by warrants (including 833,334 shares from one warrant), creating clear conversion pathways under permitted conditions.
• Certification of passive intent: The filing includes an explicit certification that the securities are not held to change or influence control.

Negative

• No sole voting or dispositive power: Each Reporting Person reports 0 shares of sole voting or dispositive power and only shared power over the reported shares.
• Blocker provisions limit conversion: Significant warrant amounts are excluded from current beneficial ownership because they cannot be exercised to the extent they would increase ownership above 9.99% or 4.99%, capping near-term upside in governance influence.

Insights

Financial Analyst

TL;DR: Reporting persons hold a near-10% economic position via warrants, but blocker provisions and shared power limit immediate control.

The reported 838,081 share position (about 9.99%) is economically meaningful for a small-cap structure and derives largely from warrant exposure (833,334 shares from one warrant). However, the reporters state 0 shares of sole voting or dispositive power and instead report shared control, which constrains their ability to unilaterally influence governance. Multiple warrants contain explicit blocker provisions that prevent conversion if doing so would exceed 9.99% or 4.99% ownership thresholds; without those blockers the position would nominally rise to 2,392,524 shares. For market impact, this filing signals a material passive economic stake but limited immediate governance influence.

Corporate Governance Expert

TL;DR: The filing documents material warrant-based exposure but affirms passive intent and structural limits on voting influence.

The certification in the filing explicitly states the holdings were not acquired to change control, consistent with a Schedule 13G filing stance. The Reporting Persons disclose shared voting and dispositive power over 838,081 shares and emphasize several warrants include blocker provisions that restrict exercise to avoid surpassing specified ownership caps. From a governance perspective, the combination of shared power and contractual blocker protections reduces the likelihood of an immediate control contest, while leaving open the possibility of increased economic exposure if blockers are removed or restructured in the future.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Silo Pharma, Inc

(Name of Issuer)

Common stock, par value $0.0001 per share

(Title of Class of Securities)

82711P201

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 82711P201

1

Names of Reporting Persons

Mitchell P. Kopin

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 838,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 838,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

838,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 82711P201

1

Names of Reporting Persons

Daniel B. Asher

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 838,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 838,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

838,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 82711P201

1

Names of Reporting Persons

Intracoastal Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 838,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 838,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

838,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.99 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Silo Pharma, Inc
(b)	Address of issuer's principal executive offices: 677 N. Washington Boulevard, Sarasota, FL 34236
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual ("Mr. Kopin"), (ii) Daniel B. Asher, an individual ("Mr. Asher") and (iii) Intracoastal Capital LLC, a Delaware limited liability company ("Intracoastal" and together with Mr. Kopin and Mr. Asher, collectively the "Reporting Persons").
(b)	Address or principal business office or, if none, residence: The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483. The principal business office of Mr. Asher is 1011 Lake Street, Suite 311, Oak Park, Illinois 60301.
(c)	Citizenship: Mr. Kopin is a citizen of the United States of America. Mr. Asher is a citizen of the United States of America. Intracoastal is a Delaware limited liability company.
(d)	Title of class of securities: Common stock, par value $0.0001 per share
(e)	CUSIP No.: 82711P201
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of the close of business on June 30, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 838,081 shares of Common Stock, which consisted of (i) 833,334 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal ("Intracoastal Warrant 1") and (ii) 4,747 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal ("Intracoastal Warrant 2"), and all such shares of Common Stock represent beneficial ownership of approximately 9.99% of the Common Stock, based on (1) 7,207,792 shares of Common Stock outstanding as of May 16, 2025, as reported to the Reporting Persons by the Issuer, plus (2) 343,334 shares of Common Stock issued to Intracoastal upon exercise of a warrant previously held by Intracoastal, (4) 833,334 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 and (5) 4,747 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2. The foregoing excludes (I) 828,587 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 9.99% of the Common Stock, (II) 344,037 shares of Common Stock issuable upon exercise of a third warrant held by Intracoastal ("Intracoastal Warrant 3") because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock and (III) 381,819 shares of Common Stock issuable upon exercise of a fourth warrant held by Intracoastal ("Intracoastal Warrant 4") because Intracoastal Warrant 4 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 4 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder's affiliates, and any other persons acting as a group together with the holder or any of the holder's affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,392,524 shares of Common Stock.
(b)	Percent of class: 9.99%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 838,081
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 838,081
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Mitchell P. Kopin

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin
Date:	08/12/2025

Daniel B. Asher

Signature:	/s/ Daniel B. Asher
Name/Title:	Daniel B. Asher
Date:	08/12/2025

Intracoastal Capital LLC

Signature:	/s/ Mitchell P. Kopin
Name/Title:	Mitchell P. Kopin, Manager
Date:	08/12/2025

FAQ

How many Silo Pharma (SILO) shares do the reporting persons beneficially own?

The Reporting Persons report beneficial ownership of 838,081 shares, representing approximately 9.99% of the outstanding common stock.

What portion of the 838,081 shares comes from warrants?

833,334 of the reported shares are issuable upon exercise of one warrant and 4,747 are issuable upon exercise of a second warrant.

Do the reporting persons have sole voting or dispositive power over these shares?

No. Each reporting person reports 0 shares of sole voting power and 0 shares of sole dispositive power; they report shared voting and dispositive power over the 838,081 shares.

Are there restrictions that prevent exercise of additional warrants?

Yes. Several warrants include blocker provisions preventing exercise to the extent that such exercise would result in beneficial ownership above specified thresholds (e.g., 9.99% or 4.99%), and certain large warrant amounts are therefore excluded from current ownership calculations.

How many shares would the Reporting Persons beneficially own without the blocker provisions?

The filing states that without the blocker provisions the Reporting Persons may have been deemed to beneficially own 2,392,524 shares.